FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an antibody for specific binding with an interleukin 4 (IL-4) receptor (IL-4R). A nucleic acid molecule encoding the specified antibody; an expression vector, a host cell, containing the specified nucleic acid molecule; a pharmaceutical composition, fused protein, and conjugate, containing the specified antibody, are also disclosed. A method for the production of the specified antibody; the use of the specified antibody, fused protein or conjugate for the manufacture of a drug; a method for the treatment, prevention or relief of severity of an inflammatory or allergic disease, using the specified antibody, are disclosed.
EFFECT: invention has a capability of effective treatment of diseases associated with interleukin 4 (IL-4) receptor (IL-4R).
32 cl, 5 dwg, 15 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST TNFRSF9 AND THEIR USE | 2019 |
|
RU2812200C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
| ANTIBODIES AGAINST OX40 AND THEIR USE | 2017 |
|
RU2783314C2 |
| ANTIBODIES AGAINST CTLA4 AND THEIR USE | 2017 |
|
RU2779312C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
